A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06498986
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT06493864
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT06475131
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 332
- Registration Number
- NCT06475300
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT06471205
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT06469008
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06445400
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06437509
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT06437522
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06423885
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath